Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-36,334
Closed -$905K 157
2025
Q4
$905K Buy
36,334
+594
+2% +$15K 0.42% 42
2025
Q3
$911K Buy
+35,740
New +$882K 0.44% 41
2023
Q3
Sell
-8,657
Closed -$318K 114
2023
Q2
$318K Buy
8,657
+564
+7% +$22K 0.17% 68
2023
Q1
$330K Buy
8,093
+105
+1% +$4.54K 0.18% 65
2022
Q4
$409K Sell
7,988
-46
-0.6% -$2.21K 0.24% 62
2022
Q3
$352K Buy
8,034
+227
+3% +$11K 0.19% 68
2022
Q2
$409K Buy
7,807
+64
+0.8% +$3.26K 0.21% 64
2022
Q1
$401K Sell
7,743
-5,847
-43% -$303K 0.18% 75
2021
Q4
$803K Buy
13,590
+1,250
+10% +$61.9K 0.36% 38
2021
Q3
$531K Buy
+12,340
New +$547K 0.25% 46

Other funds holding PFE

IRON Financial's PFE Position: Q1 2026 in Review

IRON Financial sold out of Pfizer (PFE) in Q1 2026, closing a stake of 36,334 shares — an estimated $905K sold.

IRON Financial first reported a position in PFE in Q3 2021 and held it in 10 quarters. The position peaked at $911K in Q3 2025. 2,939 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • IRON Financial reported no remaining Pfizer position as of Q1 2026 after selling out during the quarter.
  • IRON Financial sold 36,334 Pfizer shares in Q1 2026, an estimated $905K.
  • IRON Financial first reported a position in Pfizer in Q3 2021 and held it in 10 quarters.
  • IRON Financial's Pfizer position peaked at $911K in Q3 2025.
  • 2,939 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on IRON Financial's 13F filing for Q1 2026, filed 27 Apr 2026.